China
· Delayed Price · Currency is CNY China National Accord Medicines Corporation Statistics
Total Valuation
China National Accord Medicines Corporation has a market cap or net worth of CNY 14.41 billion. The enterprise value is 19.43 billion.
| Market Cap | 14.41B |
| Enterprise Value | 19.43B |
Important Dates
The next estimated earnings date is Tuesday, April 8, 2025.
| Earnings Date | Apr 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
China National Accord Medicines Corporation has 556.57 million shares outstanding. The number of shares has increased by 0.45% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 556.57M |
| Shares Change (YoY) | +0.45% |
| Shares Change (QoQ) | +1.74% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 14.60% |
| Float | 237.64M |
Valuation Ratios
The trailing PE ratio is 10.52 and the forward PE ratio is 15.60. China National Accord Medicines Corporation's PEG ratio is 3.12.
| PE Ratio | 10.52 |
| Forward PE | 15.60 |
| PS Ratio | 0.21 |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | 6.30 |
| P/OCF Ratio | n/a |
| PEG Ratio | 3.12 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.90, with an EV/FCF ratio of 7.93.
| EV / Earnings | 13.17 |
| EV / Sales | 0.26 |
| EV / EBITDA | 5.90 |
| EV / EBIT | 10.12 |
| EV / FCF | 7.93 |
Financial Position
The company has a current ratio of 1.45, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.45 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 2.10 |
| Debt / FCF | 2.81 |
| Interest Coverage | 7.29 |
Financial Efficiency
Return on equity (ROE) is 7.62% and return on invested capital (ROIC) is 4.30%.
| Return on Equity (ROE) | 7.62% |
| Return on Assets (ROA) | 2.34% |
| Return on Capital (ROIC) | 4.30% |
| Revenue Per Employee | 1.91M |
| Profits Per Employee | 37,393 |
| Employee Count | 39,449 |
| Asset Turnover | 1.47 |
| Inventory Turnover | 7.91 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.09% in the last 52 weeks. The beta is 0.40, so China National Accord Medicines Corporation's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -6.09% |
| 50-Day Moving Average | 29.87 |
| 200-Day Moving Average | 31.01 |
| Relative Strength Index (RSI) | 31.85 |
| Average Volume (20 Days) | 4,047,530 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, China National Accord Medicines Corporation had revenue of CNY 75.36 billion and earned 1.48 billion in profits. Earnings per share was 2.64.
| Revenue | 75.36B |
| Gross Profit | 8.61B |
| Operating Income | 1.92B |
| Pretax Income | 2.01B |
| Net Income | 1.48B |
| EBITDA | 2.12B |
| EBIT | 1.92B |
| Earnings Per Share (EPS) | 2.64 |
Balance Sheet
The company has 5.43 billion in cash and 6.90 billion in debt, giving a net cash position of -1.47 billion or -2.63 per share.
| Cash & Cash Equivalents | 5.43B |
| Total Debt | 6.90B |
| Net Cash | -1.47B |
| Net Cash Per Share | -2.63 |
| Equity (Book Value) | 21.65B |
| Book Value Per Share | 32.52 |
| Working Capital | 12.59B |
Cash Flow
In the last 12 months, operating cash flow was 2.75 billion and capital expenditures -301.20 million, giving a free cash flow of 2.45 billion.
| Operating Cash Flow | 2.75B |
| Capital Expenditures | -301.20M |
| Free Cash Flow | 2.45B |
| FCF Per Share | 4.40 |
Margins
Gross margin is 11.42%, with operating and profit margins of 2.55% and 1.96%.
| Gross Margin | 11.42% |
| Operating Margin | 2.55% |
| Pretax Margin | 2.67% |
| Profit Margin | 1.96% |
| EBITDA Margin | 2.81% |
| EBIT Margin | 2.55% |
| FCF Margin | 3.25% |
Dividends & Yields
This stock pays an annual dividend of 0.68, which amounts to a dividend yield of 2.45%.
| Dividend Per Share | 0.68 |
| Dividend Yield | 2.45% |
| Dividend Growth (YoY) | -15.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 36.95% |
| Buyback Yield | -0.45% |
| Shareholder Yield | 2.00% |
| Earnings Yield | 9.51% |
| FCF Yield | 15.86% |
Stock Splits
The last stock split was on June 1, 2023. It was a forward split with a ratio of 1.3.
| Last Split Date | Jun 1, 2023 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
China National Accord Medicines Corporation has an Altman Z-Score of 2.53. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.53 |
| Piotroski F-Score | n/a |